Publications by authors named "C Bustios"
Digestive diseases are the fourth leading cause of outpatient care in Peruvian healthcare centers, with gastritis and peptic ulcers being the most common. This is a retrospective, cross-sectional, descriptive study of secondary analysis of medical record data to evaluate the prevalence of Helicobacter pylori in patients undergoing upper digestive endoscopy during 2019 at Clinica Delgado, Lima, Peru. An association between males (PRa 1.
View Article and Find Full Text PDFIntroduction And Objectives: Viral infections have been described to increase the risk of decompensation in patients with cirrhosis. We aimed to determine the effect of SARS-CoV-2 infection on outcome of hospitalized patients with cirrhosis and to compare the performance of different prognostic models for predicting mortality.
Patients: We performed a prospective cohort study including 2211 hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020 through October 1, 2020 in 38 Hospitals from 11 Latin American countries.
Introduction & Objectives: The independent effect of liver biochemistries as a prognostic factor in patients with COVID-19 has not been completely addressed. We aimed to evaluate the prognostic value of abnormal liver tests on admission of hospitalized patients with COVID-19.
Materials & Methods: We performed a prospective cohort study including 1611 hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020 through July 31, 2020 in 38 different Hospitals from 11 Latin American countries.
[Virological breakthrough in treating hepatitis B with entecavir: it means resistance?].
Rev Gastroenterol Peru
January 2014
Article Synopsis
- A 45-year-old man diagnosed with chronic hepatitis B in 2008 developed cirrhosis and liver cancer, leading to a hepatectomy and treatment with Entecavir.
- After experiencing a relapse in 2009 and undergoing ethanol treatment, he effectively managed his condition and maintained therapy with Entecavir.
- In April 2010, he encountered a virological breakthrough, prompting the addition of Tenofovir; as of April 2012, his viral load was undetectable, raising concerns about potential resistance to Entecavir.
Aim: To determine if prophylaxis with cefazolin produces a significant reduction in infections in cirrhotic patients with gastrointestinal bleeding when compared with ciprofloxacin.
Methods: Randomized clinical trial. Patients 18 years or older with diagnosis of cirrhosis, gastrointestinal bleeding and no clinical or laboratory evidence of infection who were admitted to the gastrointestinal bleeding unit of HNERM between July 2008 and July 2010 were included.